Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021.
Jessica Beser, Ilias Galanis, Theresa Enkirch, Sharon Kühlmann Berenzon, Edward van Straten, Jan Duracz, Marie Rapp, Katherina Zakikhany, Mikael Mansjö, Julia Wigren Byström, Mattias N E Forsell, Ramona Groenheit, Karin Tegmark Wisell, Andreas Bråve
Author Information
Jessica Beser: Public Health Agency of Sweden, Solna, Sweden. jessica.beser@folkhalsomyndigheten.se.
Ilias Galanis: Public Health Agency of Sweden, Solna, Sweden.
Theresa Enkirch: Public Health Agency of Sweden, Solna, Sweden.
Sharon Kühlmann Berenzon: Public Health Agency of Sweden, Solna, Sweden.
Edward van Straten: Public Health Agency of Sweden, Solna, Sweden.
Jan Duracz: Public Health Agency of Sweden, Solna, Sweden.
Marie Rapp: Public Health Agency of Sweden, Solna, Sweden.
Katherina Zakikhany: Public Health Agency of Sweden, Solna, Sweden.
Mikael Mansjö: Public Health Agency of Sweden, Solna, Sweden.
Julia Wigren Byström: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
Mattias N E Forsell: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
Ramona Groenheit: Public Health Agency of Sweden, Solna, Sweden.
Karin Tegmark Wisell: Public Health Agency of Sweden, Solna, Sweden.
Andreas Bråve: Public Health Agency of Sweden, Solna, Sweden.
A national point seroprevalence study of SARS-CoV-2 was conducted in Sweden in April-May 2021. In total, 2860 individuals 3 to 90 years old from a probability-based web panel were included. Results showed that an estimated 32.6% of the population in Sweden had detectable levels of antibodies, and among non-vaccinated 20.1% had detectable levels of antibodies. We tested for differences in seroprevalence between age groups and by sex and estimated seroprevalence among previously infected participants by time since reporting.
References
MMWR Morb Mortal Wkly Rep. 2020 Nov 27;69(47):1762-1766
[PMID: 33237893]
